Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.

Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL.

Mod Pathol. 2001 Nov;14(11):1079-86.

2.

[HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].

Akhdar A, Bronsard M, Lemieux R, Geha S.

Ann Pathol. 2011 Dec;31(6):472-9. doi: 10.1016/j.annpat.2011.10.013. Epub 2011 Nov 26. Review. French.

PMID:
22172120
3.

Hidden HER-2/neu-positive breast cancer: how to maximize detection.

Carney WP.

IDrugs. 2009 Apr;12(4):238-42. Review.

PMID:
19350468
4.

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.

Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF.

J Clin Oncol. 2009 Mar 10;27(8):1323-33. doi: 10.1200/JCO.2007.14.8197. Epub 2009 Feb 9. Review.

PMID:
19204209
5.

Breast cancer in the 21st century: neu opportunities and neu challenges.

Schnitt SJ.

Mod Pathol. 2001 Mar;14(3):213-8. Review.

6.
7.

Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer.

Sahin AA.

Adv Anat Pathol. 2000 May;7(3):158-66. Review.

PMID:
10809222
8.

[HER-2 diagnostics].

Bánkfalvi A.

Magy Onkol. 2002;46(1):11-5. Epub 2003 Feb 3. Review. Hungarian.

9.

Prognostic and predictive value of HER2/neu oncogene in breast cancer.

Masood S, Bui MM.

Microsc Res Tech. 2002 Oct 15;59(2):102-8. Review.

PMID:
12373720
10.

Her-2/neu and breast cancer.

Kaptain S, Tan LK, Chen B.

Diagn Mol Pathol. 2001 Sep;10(3):139-52. Review.

PMID:
11552716
11.

HER2 testing in breast cancer: NCCN Task Force report and recommendations.

Carlson RW, Moench SJ, Hammond ME, Perez EA, Burstein HJ, Allred DC, Vogel CL, Goldstein LJ, Somlo G, Gradishar WJ, Hudis CA, Jahanzeb M, Stark A, Wolff AC, Press MF, Winer EP, Paik S, Ljung BM; NCCN HER2 Testing in Breast Cancer Task Force.

J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. Review.

PMID:
16813731
12.

Systematic review of HER2 breast cancer testing.

Cuadros M, Villegas R.

Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):1-7. doi: 10.1097/PAI.0b013e318169fc1c. Review.

PMID:
18685491
13.

The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.

Ross JS, Fletcher JA.

Semin Cancer Biol. 1999 Apr;9(2):125-38. Review.

PMID:
10202134
14.

Predicting the clinical course of breast cancer patients undergoing trastuzumab-based therapy: an outlook.

Hudelist G, Köstler W, Czerwenka K, Kubista E, Singer CF.

Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):201-10. Review.

PMID:
15148526
15.

Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing.

Cell Markers And Cytogenetics Committees College Of American Pathologists.

Arch Pathol Lab Med. 2002 Jul;126(7):803-8. Review.

PMID:
12088449
16.

Recent trends of HER-2 testing and trastuzumab therapy for breast cancer.

Kurosumi M.

Breast Cancer. 2009;16(4):284-7. doi: 10.1007/s12282-009-0159-z. Epub 2009 Aug 6. Review.

PMID:
19657709
18.

HER-2/neu testing in breast cancer.

Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Hortobagyi GN.

Am J Clin Pathol. 2003 Dec;120 Suppl:S53-71. Review.

PMID:
15298144
19.

[Current review and status of IHC and FISH in breast carcinoma. Role of further diagnostic methods].

Lebeau A.

Onkologie. 2002 Dec;25 Suppl 5:5-7. Review. German. No abstract available.

PMID:
23573610
20.

Prevalence of HER-2-positive invasive breast cancer: a systematic review from Iran.

Keyhani E, Muhammadnejad A, Karimlou M.

Asian Pac J Cancer Prev. 2012;13(11):5477-82. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk